Supplementary Figure 2S - Lineweaver-Burk diagram for the substrate RH123 (A) and CFDA (B) in the absence (vehicle, DMSO) or presence of nilotinib (1-10 μM). from Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma